Myosana Therapeutics
Seattle, US · Founded 2018 · Delaware corporation
Myosana Therapeutics develops non-viral, muscle-targeted gene therapies aimed at slowing skeletal muscle degeneration and heart failure in Duchenne muscular dystrophy (DMD) and other neuromuscular and cardiac diseases. The company works in the biotech and gene therapy field.
Founders & leadership
Myosana Therapeutics was founded in 2018 by Stanley C. Froehner, Nicholas P. Whitehead, Stan Froehner, and Nick Whitehead.
Reported raises · per SEC filings
Form D private placements$6.4M disclosed across 1 round · 2022
▶$6.4MraisedDec 2022 · 6 investors · OtherRule 506(b)
▶$6.4MraisedDec 2022 · 6 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Matthew LumleyDirector
- Stanley C. FroehnerExecutive Officer, Director, Promoter
- Debra MillerDirector
- Nicholas P. WhiteheadExecutive Officer, Director, Promoter
- Offering amount
- $6.4M
- Amount sold
- $6.4M
- First sale
- Nov 2022
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
Day One Biopharmaceuticals6 shared keywordsDay One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors. Founded in 2018, it received its first FDA approval in 2024 for a pediatric brain tumor treatment.
Sionnatx5 shared keywordsSionna Therapeutics is a biopharmaceutical company founded in 2019 that develops small-molecule therapies for cystic fibrosis by targeting and stabilizing NBD1, the domain of the CFTR protein where the common ΔF508 mutation occurs. It is advancing a portfolio of NBD1 stabilizers and complementary CFTR modulators intended to be used in combination to normalize CFTR function in CF patients.
Bioworld4 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Mosanna4 shared keywordsMosanna is a pharmaceutical company developing a non-invasive nasal spray therapy for obstructive sleep apnea (OSA) that reactivates the body's natural airway reflex to keep the upper airway open during sleep. Its lead candidate, MOS-118, is a small molecule delivered before bedtime that stimulates upper airway dilator muscles to reduce apnea and hypopnea episodes.
Companies competing with Myosana Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Myosana Therapeutics do?
- Myosana Therapeutics develops non-viral, muscle-targeted gene therapies aimed at slowing skeletal muscle degeneration and heart failure in Duchenne muscular dystrophy (DMD) and other neuromuscular and cardiac diseases. The company works in the biotech and gene therapy field.
- Who founded Myosana Therapeutics?
- Myosana Therapeutics was founded by Stanley C. Froehner, Nicholas P. Whitehead, Stan Froehner, Nick Whitehead in 2018.
- How much funding has Myosana Therapeutics raised?
- Myosana Therapeutics has disclosed $6.4M raised across 1 round.
- Where is Myosana Therapeutics headquartered?
- Myosana Therapeutics is headquartered in Seattle, US.